Glucocorticoid therapy is an important risk factor for osteoporosis in rheumatoid arthritis. Reduction in fracture risk is the most important endpoint for osteoporosis treatments. The aim of this study was to evaluate whether skeletal benefit (increases in osteosonogrammetry parameters, reduction in bone turnover and fracture incidence) are maintained during a follow-up of 1 year with risedronate therapy (5 mg/day). During the study period osteosonogrammetry parameters showed a significant increase and no new osteoporotic fractures were reported, suggesting an antifracture effect of risedronate therapy. Urine crosslinks (as a bone resorption marker) significantly decreased during the follow-up, suggesting a positive balance in the bone remodeling process. The tolerability of risedronate was good and only seven out of 51 patients presented minimal adverse effects. In summary, risedronate significantly decreased new osteoporotic fractures in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis and is an effective and well-tolerated treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Hua Xi Kou Qiang Yi Xue Za Zhi
February 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Objectives: This study aimed to analyze the influence of drug factors on the efficacy of bisphosphonate for chronic nonbacterial osteomyelitis to provide a reference for clinical treatment and promote clinical rational drug use by evaluation of effectiveness and safety of bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Methods: Literature on the treatment of chronic nonbacterial osteomyelitis by using bisphosphonate was collected and analyzed from PubMed, Medline, Embase, Cochrane, ISI Web of Knowledge, CNKI, VIP, and Wanfang databases.
Results: A total of 489 cases were collected, with an average complete response rate of clinical presentation, laboratory tests and imaging findings of 80.
Engineering dimer mutants of human geranylgeranyl pyrophosphate synthase.
PLoS One
January 2025
Department of Biochemistry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
Geranylgeranyl pyrophosphate synthase (GGPPS), a key enzyme in protein prenylation, plays a critical role in cellular signal transduction and is a promising target for cancer therapy. However, the enzyme's native hexameric quaternary structure presents challenges for crystallographic studies. The primary objective of this study was to engineer dimeric forms of human GGPPS to facilitate high-resolution crystallographic analysis of its ligand binding interactions.
View Article and Find Full Text PDFEldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
J Clin Endocrinol Metab
January 2025
Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Context: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR+EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
View Article and Find Full Text PDFTibial Insufficiency Fracture with Characteristics of an Atypical Fracture: A Rare Case and Literature Review.
Medicina (Kaunas)
November 2024
Department of Orthopedic Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul 07345, Republic of Korea.
Article Synopsis
- - Osteoporosis is increasingly common due to an aging population, leading to more patients using bisphosphonates for treatment, which can prevent fractures but also cause atypical insufficiency fractures over time.
- - A case study of a 76-year-old woman on long-term bisphosphonate therapy revealed an atypical insufficiency fracture in her tibia, which was confirmed through imaging and examination.
- - After conservative treatment failed, the patient underwent surgery and successfully healed, highlighting the need for clinicians to investigate unexplained pain in weight-bearing bones among individuals on prolonged bisphosphonate therapy.
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.
Eur J Endocrinol
November 2024
Department of Rheumatology, Amsterdam University Medical Center, Amsterdam 1081HV, The Netherlands.
Article Synopsis
- - The report by the European Calcified Tissue Society (ECTS) outlines evidence-based recommendations for preventing and treating glucocorticoid-induced osteoporosis (GIOP) in adults, aimed at healthcare providers who may not specialize in bone health.
- - Experts reviewed the literature and created 25 recommendations that categorize patients based on their fracture risk: medium, high, and very high, considering factors like age and history of fractures for appropriate treatment strategy.
- - Key general measures include optimizing calcium and vitamin D intake, assessing fracture risk regularly for those on glucocorticoids for three months or longer, and minimizing fall risks among patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!